Press releases

EVOLVE II trial represents the first successful U.S. pivotal trial of a bioabsorbable polymer stent

System designed for the hysteroscopic removal of interuterine fibroids and polyps

New CPT Category I code facilitates processing for U.S. hospitals and physicians

Boston Scientific will participate in the upcoming healthcare conference on November 18, 2014. A live webcast and replay will be available.

Event will be held in Chicago, site of the 2014 American Heart Association Scientific sessions

Data will focus on long-term back pain relief using the Precision Spectra™ Spinal Cord Stimulator (SCS) System and highlight research on stimulation waveforms

Boston Scientific will participate in the upcoming healthcare conference on November 11, 2014. A live webcast and replay will be available.

"We achieved excellent third quarter results,” said Mike Mahoney, Boston Scientific chairman and CEO

World's first 32-contact SCS surgical leads designed to provide more focused pain relief for patients with chronic pain

PLATINUM diversity trial evaluating performance in women, Black Americans, Latinos/Hispanics, Native Americans and Alaska Natives with Coronary Artery Disease

Innovative devices allow pacemaker patients access to full body MRI scans in 1.5 Tesla and 3.0 Tesla systems

Comprehensive clinical data from randomized trials reviewed

Boston Scientific will webcast its conference call discussing financial results and business highlights for Q3 ended September 30, 2014. Learn how to tune in.

Data from REPRISE III clinical trial designed to support U.S. regulatory approval

First DBS system to offer precise neural targeting and a 25-year battery life

No cases of moderate or severe paravalvular aortic regurgitation at one year

Data will focus on areas of significant unmet patient need, including Coronary Artery Disease and Aortic Valve Disease

Boston Scientific will participate in the upcoming healthcare conference on September 17, 2014 in London

Acquisition allows Boston Scientific to offer a more complete portfolio of solutions to treat challenging vascular conditions

Phase II feasibility trial provides first randomized sham-controlled data using vagus nerve stimulation to treat heart failure

Boston Scientific will participate in the healthcare conference on September 8 in New York

Companies reach agreement to develop a new and differentiated FFR guidewire and next generation Boston Scientific Rotablator™ RotaWire™

"We had a strong second quarter, delivering balanced growth across our divisions," said CEO Mike Mahoney

Innovative technology adds to company's leading portfolio of treatment options for Coronary Artery Disease

Easy to use imaging system to support planned intravascular ultrasound and fractional flow reserve products

Advanced bare-metal stent provides additional treatment option for interventional cardiologists and patients

European launch means physicians can now choose from three available valve sizes to match patient anatomy more precisely

Innovative technology strengthens company's leading portfolio of solutions for peripheral vascular disease

Boston Scientific will webcast its conference call with financial results and business highlights for Q2 ended June 30, 2014. Learn how to tune in.

Data presented at the 18th International Congress of Parkinson's Disease and Movement Disorders demonstrate highly significant improvement in motor function for patients with Parkinson's Disease

Data presented at the International Congress of Parkinson's Disease and Movement Disorders demonstrate superior therapeutic window for the treatment of Parkinson's Disease

Registry will collect data on clinical outcomes and device performance in 1,000 patients implanted at 50 centers around the world

Boston Scientific will participate in the healthcare conference on June 17 in Boston. Learn how to watch the webcast or replay.

Boston Scientific will participate in the healthcare conference on June 10. Learn how to watch the webcast or replay.

Study evaluated Lotus Valve System in symptomatic patients with severe aortic valve stenosis considered at high risk for surgical valve replacement

EVOLVE study data presented today at EuroPCR 2014 also demonstrate excellent safety profile

Boston Scientific reinforces its commitment to global education and innovation

Acquisition expected to strengthen peripheral interventions business and accelerate growth in peripheral atherectomy and thrombectomy categories

PREDICt-RM collaborative study between Boston Scientific, American College of Cardiology and Yale University highlights improved outcomes in ICD and CRT-D patients followed with the LATITUDE™ System.

Boston Scientific Shockless Implant Evaluation (SIMPLE) study results presented at Heart Rhythm 2014, the Heart Rhythm Society's 35th annual scientific sessions.

Advanced Illumina™ 3D Programming Software provides highly significant pain relief in study patients.

Innovative technology designed to treat intrauterine fibroids and polyps.

Global medical solutions innovator seeks to pioneer new research into effective treatments for heart failure and related cardiac conditions.

Broad set of data reinforces commitment to advancing research and technology in electrophysiology.

Promising clinical data to be presented at annual conference.

Boston Scientific will participate in the healthcare conference on May 13, 2014. Learn how to watch the webcast or replay.

Advanced drug-eluting stent system recently received Japan Ministry of Health, Labor and Welfare approval.

Company exceeds earnings per share guidance on the strength of continued revenue growth.

Clinical trial is designed to establish the safety and effectiveness of both lead families.

Event will be held in San Francisco, site of the Heart Rhythm Society 35th Annual Scientific Sessions.

Newly approved devices include the DYNAGEN™ MINI and INOGEN™ MINI ICDs, as well as the DYNAGEN™ X4 and INOGEN™ X4 CRT-Ds.

Study to evaluate clinical outcomes and economic value of the Vercise™ Deep Brain Stimulation (DBS) System.

The first implant of the S-ICD System performed in Hong Kong.

Boston Scientific Corporation (NYSE: BSX) has received clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval in Europe for the Expect™ Slimline (SL) Needle, which is...

Reinforcing its position as a global leader in bringing new therapies to patients with heart and cardiovascular disease, Boston Scientific Corporation...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2014 on...

Real-world data on the Boston Scientific Corporation (NYSE:BSX) S-ICD System (Subcutaneous Implantable Defibrillator) are highlighted online this week...

MADIT-CRT long-term follow-up results presented at the American College of Cardiology and published in the New England Journal of Medicine.

Includes late breaking clinical trial assessing use of the Boston Scientific CRT-D therapy in patients with mild heart failure

Recognition is for delivering world class results and demonstrating a strong culture of operational excellence at Maple Grove, Minnesota manufacturing facility.

First implant took place in France, at the Nouvelles Cliniques Nantaises in Nantes.

Newest bare metal stent technology features advanced architecture and provides physicians with enhanced treatment option for patients

Appointment fills a vacancy that will result from the Board's decision to increase the number of directors comprising the Board from eleven to twelve.

Boston Scientific will participate in the healthcare conference on March 11 in Miami Beach. Learn how to watch the webcast or replay.

Boston Scientific will participate in the healthcare conference on March 4 in Boston. Learn how to watch the webcast or replay.

Boston Scientific will participate in both healthcare conferences on February 26 in New York City. Learn how to watch the webcast or replay.

Fully covered metal stent provides new treatment option for patients with refractory benign esophageal strictures

System provides physicians new option for treating complete blockages in the major arteries of the leg

Fourth quarter marks third consecutive quarter of improved performance.

Boston Scientific will participate in the healthcare conference on February 12 in New York. Learn how to watch the webcast or replay.

Boston Scientific will webcast its conference call with financial results and business highlights for Q4 and full year ended December 31, 2013. Learn how to tune in.

Global leader in complex cardiac interventions to play key role in driving innovative medical solutions.

Boston Scientific will participate in the healthcare conference on January 14 in San Francisco. Learn how to watch the webcast or replay.

Latest devices to treat heart failure and sudden cardiac arrest are designed to advance patient care.

Appointment will fill a vacancy that will result from the Board's decision to increase the number of directors comprising the Board from ten to eleven.

Represents important milestone toward making WATCHMAN device available to patients with atrial fibrillation.

Data presented at NANS 2013 show highly significant reduction in pain and high trial therapy success rate in the treatment of chronic pain.

Companies will collaborate to provide promotional support for stent system in U.S. hospitals

Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug...

Boston Scientific will participate in the healthcare conference on December 3 in New York. Learn how to watch the webcast or replay.

Brings more than 20 years of financial and healthcare industry experience, including extensive knowledge of the medtech industry.

Proprietary shaft design enables better control in hard-to-navigate vessels

First system to selectively stimulate targeted areas of the brain to manage symptoms of debilitating disease

Patients In Germany receive new transcatheter aortic valve implantation devices specially designed for total control and accurate deployment.

Boston Scientific will participate in the healthcare conference on November 12 in Scottsdale, AZ. Learn how to watch the webcast or replay.

Advances Boston Scientific's ability to more comprehensively serve the rapidly expanding global EP market.

New data demonstrate successful deployment in all 120 patients with no severe paravalvular regurgitation at 30 days

Boston Scientific will participate in the healthcare conference on November 12. Learn how to watch the webcast or replay.

REDUCE-HTN data presented today at TCT demonstrate excellent safety profile.

Boston Scientific Corporation (NYSE: BSX) will highlight the strength of its advanced portfolio and plans for delivering additional meaningful...

Transcatheter Aortic Valve Replacement (TAVR) device offers precise positioning and placement, offering physicians unprecedented control.

Jeffrey Capello to transition out of CFO role at year-end

"We accelerated our operational performance in the quarter while enhancing our ability to deliver meaningful innovation,” said CEO Mike Mahoney.

Revolutionary procedure clinically proven to provide long term reduction of asthma exacerbations

Award recognizes innovative S-ICD® System, the world's first and only subcutaneous implantable defibrillator.

Boston Scientific will webcast its conference call with financial results and business highlights for Q3 ending September 30, 2013. Learn how to tune in.

MAJESTIC trial to study self-expanding DES System designed to treat superficial femoral artery (SFA) lesions.

University of Pittsburgh independent study of contemporary heart failure devices highlights industry-leading Boston Scientific battery longevity.

Re-ROUTE trial data presented at VIVA 2013 late-breaking session

Agreement settles all stent-related disputes between the companies.